CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	13.83	-0.57	-99.32	-115.87	-64.82	-132.83
Depreciation & Amortization	1.84	2.18	2.44	2.71	2.57	2.61
Asset Writedown & Restructuring Costs	-	-	0.25	-	-	-
Loss (Gain) From Sale of Investments	-6.75	-7.42	-0.05	0.27	-0.24	-2.23
Stock-Based Compensation	8.34	8.56	13.13	13.17	14.79	19.1
Other Operating Activities	3.99	3.73	3.41	3.13	2.89	4.27
Change in Accounts Receivable	-0.93	32.55	-35.2	0.01	-0.79	0.08
Change in Accounts Payable	-0.36	-1.43	0.07	-0.14	-0.86	-0.37
Change in Unearned Revenue	-107.04	-89.01	16.57	-33.95	62.83	-17.15
Change in Other Net Operating Assets	-1.2	-4.63	-12.09	11.64	-11.12	-13.96
Operating Cash Flow	-88.29	-56.04	-110.79	-119.03	5.26	-140.48
Capital Expenditures	-0.5	-0.84	-1.74	-1.61	-2.31	-3.5
Investment in Securities	97.93	-149.83	100	24.1	-16.41	83.2
Investing Cash Flow	97.43	-150.67	98.26	22.49	-18.72	79.7
Issuance of Common Stock	5.52	0.56	0.65	110.21	16.89	1.63
Other Financing Activities	-	29.67	-	-	-	-
Financing Cash Flow	5.52	30.23	0.65	110.21	16.89	1.63
Net Cash Flow	14.66	-176.48	-11.88	13.67	3.43	-59.15
Free Cash Flow	-88.78	-56.88	-112.53	-120.64	2.95	-143.98
Free Cash Flow Margin	-70.12%	-56.19%	-211.67%	-323.33%	4.31%	-535.19%
Free Cash Flow Per Share	-1.06	-0.77	-1.71	-1.88	0.06	-3.18
Cash Income Tax Paid	-	-	-	-	-	13.06
Levered Free Cash Flow	-13.73	43.66	-8.92	-46.11	-53.86	-83.19
Unlevered Free Cash Flow	-13.73	43.66	-8.92	-46.11	-53.86	-83.19
Change in Net Working Capital	27.6	-37.82	-35.9	-12.16	18.57	12.97

Source: S&P Capital IQ. Standard template. Financial Sources.